Documentos de Académico
Documentos de Profesional
Documentos de Cultura
More aggressive treatments for cancer Increase in number and types of bone marrow and solid-organ transplant procedures Increasing numbers of AIDS patients and longer surviving AIDS patients Greater numbers of other immunocompromised patients More aggressive intensive care medicine in adults New and more widely used prosthetic devices
Candida spp. Cryptococcus Other Yeasts Aspergillus spp. Fusarium spp. Zygomycetes
C. albicans,* non-albicans Candida spp.* C. neoformans Trichosporon species, Blastoschizomyces species *A. fumigatus, A. terreus, A. flavus, A. niger, and others F. solani, F. oxysporum, and others Rhizopus spp., Mucor, Absidia
Dermatophytes (Tinea)
Systemic Mycoses
Coccidiodes immitis Coccidiomycosis. Histoplasma capsulatum intracellular mycosis of the RES. Blasomyces dermatitidis lungs and may disseminate to skin and other sites.
4
Opportunistic Mycoses
Candida
albicans mouth (thrush), female genitalia (vulvovaginitis), skin and nails. Disseminated: thrombophlebitis, endocarditis, and involvement in other organs such as the lungs and kidneys. fourth leading cause of bloodstream infections. Cryptococcus neoformans meningitis in AIDS patients. Aspergillus lung, brain, sinuses, or other organs in some immunosuppressed patients. Mucormycosis sinuses, eyes, blood, brain.
5
Antifungal Drugs
Azoles:
Imidazoles: Ketoconazole (systemic) Clotrimazole, miconazole (topical) Triazoles: Itraconazole, Fluconazole, voriconazole Allylamines: Terbinafine
Echinocandins
Inhibition of cell wall synthesis
Zymosterol
Fecosterol Ergosterol Polyenes
9
Polyene antifungals
10
Spectrum of Activity
Polyene antibiotics
Amphotericin B. Interaction with ergosterol, Lipid formulation of formation of aqueous channels, amphotericin B. increased membrane permeability Nystatin. to univalent and divalent cations,
cell death. Candida spp., Aspergillus spp, other filamentous fungi,
Coccidioides immitis,
Histoplasma capsulatum, Blastomyces dermatidis.
ergosterol
+ a polyene
11
Amphotericin B
Fungicidal, discovered in 1956 Streptomyces nodosus Mechanism of Action The selective effect is achieved because the sterol in highest concentration is ergosterol and polyenes have a high affinity for ergosterol. The membranes become leaky. Ergosterol has two conjugated double bonds that is lacking in mammalian membrane steroids (mainly cholesterol).
12
Pharmacokinetics
not absorbed orally. It is given as a colloidal dispersion by slow iv infusion. i.v, topical and intrathecal (never be given
intramuscular)
It is highly bound to cholesterol-lipoprotein, plasma t - 24 hrs and 1-2 weeks from tissues mostly metabolized in liver (60%) some is excreted by kidney does not readily pass the blood-brain barrier
13
Topically for oral, vaginal and cutaneous candidiasis and otomycosis Leishmaniasis
14
Adverse Effects
Reactions on infusion - headache, fever, chills, anorexia, vomiting, muscle and joint pain. Pain at site of injection and thrombophlebitis Nephrotoxicity - chronic renal tox in up to 80% of patients - most common limiting toxicity of the drug. Hematologic - anemia due to BM depression Other less common reactions - neuropathy, hearing loss, allergic, etc. Drug interactions- Aminoglycosides, cyclosporine, vancomycin
15
17
Nystatin
18
Nystatin
19
Natamycin
supplied as a 5% ophthalmic suspension for the treatment of fungal conjunctivitis, blepharitis and keratitis.
20
Flucytosine
21
synthesized in 1957 as an antitumor agent. Narrow spectrum fungistatic Cryptococcus neoformans, chromoblastomyces and few Candida spp.
5-fluorouracil
Phosphoribosyl transferase 5-dFUMP
dTMP
23
RNA
dUMP
Uses
used with amphotericin B (cryptococcal meningitis) and with itraconazole (chromoblastomyosis).
Resistance is common.
25
Untoward effects
nausea, vomiting, marked diarrhoea bone marrow suppression leucopenia, anemia and thrombocytopenia alopecia mild reversible liver dysfunction
26
AZOLE ANTIFUNGALS
27
Structure of Azoles
Imidazoles
Triazoles
Lanosterol demethylase
Spectrum of activity - Dermatophytes, candida spp., C.immitis. Cryptococcus sp., Staph aureus, strep faecalis, Bact Fragilis and leishmania (NOT Aspergillus sp, non candida albicans sp) 29
Ketoconazole (KCZ)
Oral, broad spectrum Most of the use of this drug for significant fungal infections has been replaced by fluconazole and itraconazole.
Pharmacokinetics
Absorption variable (better in acidic medium) Half life -1-6 hrs Poor concentration in CSF Metabolized by Cyt. P450 enzymes
31
Therapeutic Use:
Dermatophytosis Oral, esophageal, mucocutaneous, vaginal candidiasis coccidiomycosis, histoplasmosis if not severely ill or immunocompromized. Dose 200mg OD or BD
Drug interactions CYP3A4 inhibitor- raises warfarin, phenytoin, sulfonylurea levels Polymorphic ventricular tachycardia with cisapride, astemizole, terfenadine
32
Adverse Effects
Headache, rash, loss of appetite - Endocrine: menstrual abnormalities, gynaecomastia, azoospermia, decreased libido and potency - Hypertension and fluid retention - mild hepatotoxicity (10%), fatal Hepatitis (rare 1/10,000 )
-
Topical imidazoles
Clotrimazole Tinea infections Athletes foot Otomycosis Candidiasis- vaginal, oral, cutaneous Corynebacterial skin infections
Fluconazole (FCZ).
Oral and IV. Broader spectrum of activity than KCZ Longer acting, safer and more efficacious Indications Candidiasis (oral, esophageal, cutaneous, vaginal) in immunocompromised Coccidoidal meningitis and histoplasmosis Cryptococcus infections inc Cryptococcal meningitis Dermatophytosis Fungal keratitis
35
Adverse effects
N,V, abdominal pain, rash and headache. A few reports of severe hepatotoxicity and 1% show an increase in transaminases. ventricular tachycardia with cisapride No inhibition of steroid synthesis Not as potent an inhibitor of P450 as KCZ
Itraconazole (ICZ).
Oral and IV, also a suspension.. broader activity than KCZ or FCZ DOC for paracoccidiodomycosis and chromomycosis Aspergillosis histoplasmosis, blastomycosis, sporotrichosis oral and esophageal candidiasis. dermatophytic infections of the toenail and fingernail (Tinea unguium) less effective than FCZ
37
Indications
Adverse Effects
nausea, Gastric intolerance Dizziness, pruritis, headache rash elevated transaminases; a few reports of severe hepatotoxicity. Ventricular arrythmias with terfenadine
39
Voriconazole
Voriconazole (VCZ).
Introduced in 2002 oral, i.v Spectrum of activity - superior than fluconazole (4-16 fold) & itraconazole
Indication
Invasive aspergillosis Refractory candida infections Oropharyngeal candidiasis Refractory Fusarium & Scedosporium infection
41
Pharmacokinetic
Route of administration Bioavailability (%) Half-life (hr) Primary route of elimination
Allylamines
43
Terbinafine
Oral and topical more limited spectrum of activity than the azoles fungicidal effective against dermatophytes and candida.
44
Zymosterol
Fecosterol Ergosterol Polyenes
46
Pharmacokinetics
Indications Treatment of onychomycosis of the toenail or fingernail due to dermatophytes.
Candidiasis
47
Adverse Effects
Gastric upset, rash, taste disturbance monitor CBC and hepatic function in patients receiving long term therapy now has a boxed warning on rare hepatotoxicity; maybe 1/50,000 treated; Erythema, itching, dryness, rashes with topical use no significant drug interactions
48
Griseofulvin
49
Griseofulvin
Antibiotic produced from Penicillium griseofulvum. Oral Fungistatic Mechanism of action Binds to microtubules/ disrupts mitosis multinucleated and stunted fungal hyphae Dermatophytes actively concentrate it incorporates into keratin precursor cells and ultimately into keratin which cannot then support fungal growth
50
Indications
Infections of skin, hair, nails; Prolonged therapy until new tissue replaces old diseased tissue. Dose- 125-250 mg QID
Toe nails
8-12 months
51
Pharmacokinetics
used orally, not topically metabolized in liver f/b renal excretion t ~ 24 hours
CYP 3A4 inducer induces warfarin metabolism and reduces Oral Contraceptive efficacy
52
Adverse effects
53
Echinocandins
54
Echinocandins
Novel MOA - Inhibit 1,3--D glucan synthase
Spectrum of activity Rapidly fungicidal against most Candida spp. & Aspergillus spp. Active against Histoplasma, Blastomyces and cyst form of Pneumocystis carinii Not active against Cryptococcus neoformans
55
Pharmacokinetic Parameters
Caspofungin Bioavailability (%) Protein Binding (%) Half-life (hr) Primary route of elimination
Poor (<1%)
97 9-11 Hepatic
56
Caspofungin
Indications Invasive aspergillosis. Candidemia and the following Candida infections: Intra-abdominal abscesses, esophageal, peritonitis and pleural space infections. As effective and less toxic than amphotericin B in treatment of fungal infections.
57
Adverse effects
Fever Nausea, vomiting Headache Phlebitis Histamine release reaction Rash infrequent
58
LIMITATIONS
Exhibits significant toxicities. Frequent treatment failures. Chemically unstable. No oral formulation.
High cost (20-50 times). Only topical formulation. Emergence of Resistance. Fungistatic. Significant drug interaction potential. Toxicity on long term use.
Emergence of Resistance. Narrow spectrum of activity. Toxicity. Narrow spectrum of activity. Fungistatic.
63
Topical Antifungals
64
Topical Antifungals
Many azoles; nystatin (Candida only); Tolnaftate; naftifine; terbinafine; Undecylenic Acid , Whitfields ointment (Benzoic+Salicylic Acid)
65
Tinea infections
FIGURE 1. Kerion, a severely inflammatory, boggy, indurated, tumor-like mass that may occur in tinea 66 capitis
Tinea barbae
67
Tinea Corporis
68
Tinea cruris
69
70
71